- Home
- LU vs IRON Comparison
LU vs IRON Comparison
Compare LU & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | IRON |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LU | IRON |
|---|---|---|
| Price | $1.95 | $67.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $2.00 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 928.1K | 268.5K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.52 | $283.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.73 | $40.00 |
| 52 Week High | $4.57 | $99.50 |
Technical Indicators
Market Signals| Indicator | LU | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 50.34 |
| Support Level | $1.73 | $57.79 |
| Resistance Level | $2.77 | $69.36 |
| Average True Range (ATR) | 0.08 | 2.52 |
| MACD | 0.02 | -0.45 |
| Stochastic Oscillator | 36.21 | 29.74 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.